drug · small molecule

VRAYLAR

updated 3mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.

targets

D(2) dopamine receptorD(3) dopamine receptor

all catalysts(0)

nothing on the calendar yet

Trials studying VRAYLAR

phase3A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenianot yet recruitingn=84

News(2)

As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
biospace · 1d ago
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
biospace · 11d ago

brand

VRAYLAR

trade names

Reagila, Vraylar

generic

CARIPRAZINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action The mechanism of action of cariprazine is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at serotonin 5-HT 2A receptors. Cariprazine forms two major metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

indication

1 . INDICATIONS AND USAGE VRAYLAR ® is indicated for: • Treatment of schizophrenia in adult and pediatric patients 13 years of age and older [see Clinical Studies ( 14.1 )] • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older [see Clinical Studies ( 14.2 )] • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients [see Clinical Studies ( 14.3 )] • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients [see Clinical Studies ( 14.4 )] VRAYLAR is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults and pediatric patients 13 years of age and older ( 1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients 10 years of age and older ( 1 ) Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults ( 1 ) Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(2)

As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door

Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…

biospace · 1d ago

AbbVie shares pressured as Q2 I&I beat falls below investor expectations

AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.

biospace · 11d ago

VRAYLAR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VRAYLAR

News(2)

Report a data issue

comments(0)

VRAYLAR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VRAYLAR

News(2)

Report a data issue

comments(0)